Head Trauma in Pro Athletes Linked to Motor Neuron Disease

Football Players and Boxers with ALS-Like Condition Show Specific Patterns of Protein Deposits in Brain

Newswise — Professional athletes with repetitive head trauma—and possibly others with a history of head injuries many years previously—may be prone the development of a motor neuron disease similar to amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), reports a study in the September Journal of Neuropathology & Experimental Neurology, official journal of the American Association of Neuropathologists, Inc. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and busines.s intelligence for students, professionals, and institutions in ww, w, allied health, pharmacy and the pharmaceutical industry.

"This is the first pathological evidence that repetitive head trauma experienced in collision sports might be associated with the development of a motor neuron disease," according to the study by Dr. Ann C. McKee of Boston University School of Medicine and colleagues.

Specific Brain Abnormalities Linked to Motor Neuron Disease in Athletes with Head TraumaThe researchers used sophisticated neuropathology techniques to study specific proteins, called tau and TDP-43, in brains obtained at autopsy from twelve former athletes. Eleven of the athletes had been professional football players or boxers; one was a hockey player.

All of the athletes had a newly characterized disease called chronic traumatic encephalopathy (CTE), with dementia developing many years after a history of repeated concussions. Previous studies have linked CTE to the deposits of tau and TDP-43 in the brain, in the absence of abnormalities typically associated with Alzheimer's disease.

In addition to CTE, three of the athletes were affected by fatal motor neuron disease, with profound and progressive muscle weakness and deterioration for several years before death. Motor neuron diseases—the most familiar of which is ALS—are characterized by degeneration of the specialized nerve cells controlling muscle movement and organ function.

The brains from patients with CTE and motor neuron disease showed specific patterns of tau and TDP-43 deposits, distinct from those of sporadic ALS. In the cases of CTE and motor neuron disease, the abnormalities included deposits of tau and TDP-43 extending into the spinal cord.

Previous studies had suggested a possible link between repetitive head trauma and the development of motor neuron disease. The new findings help to explain the association of ALS with head injury—and may provide clues as to the cause of ALS.

Of course, most people who develop ALS are not pro athletes. "The study has broad implications, not only for understanding the potential risks to professional and non-professional athletes in many types of collision sports, but also for people who serve in military combat," comments Dr. Raymond A. Sobel, Editor-in-Chief of Journal of Neuropathology & Experimental Neurology. "Anyone who experiences repetitive, seemingly mild, head injury or concussion might be at risk for developing a brain disease later in life."

Critical research questions remain, according to Dr. McKee and colleagues. It's unknown exactly how brain injury leads to protein deposits, or whether head trauma produces these changes alone or in association with certain genetic factors. The fact that symptoms don't develop for many years after head trauma may provide an opportunity for some type of treatment to block or reduce the "neurodegenerative cascade" triggered by such injuries.

The results also highlight the need for further autopsy brain studies. "We do not understand important neurological diseases such as ALS, Alzheimer disease, and Parkinson disease and we cannot diagnose them accurately other than by examination at autopsy," Dr. Sobel adds. "We can only advance research in these diseases and develop effective treatments for them by learning from autopsy studies."

About Journal of Neuropathology & Experimental Neurology Journal of Neuropathology & Experimental Neurology is the official journal of the American Association of Neuropathologists, Inc. The Journal publishes original articles on neuropathology and experimental neuroscience, book reviews, letters, and Association news. It is written by and for neuropathologists, neurologists, neurosurgeons, pathologists, psychiatrists, and basic neuroscientists from around the world. Publication has been continuous since 1942.

About The Americhe American an Association of NeuropathologistsFor over 80 years,The American Association of Neuropathologists, Inc. (AANP), has been dedicated to advancing the science and practice of neuropathology. The AANP has grown to include over 800 members, recognized for their contributions to neuropathology research and practice, in the United States and abroad. In addition to producing JNEN, the AANP holds an annual meeting each June, including courses and symposia on topics of special interest as well as scientific sessions.

Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.

LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Note: Learn more and access the full text article from the Journal of Neuropathology & Experimental Neurology website at: www.jneuropath.comLWW